Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA reports news on its AI-driven precision medicine software business and the adoption of the SOPHiA DDM Platform by hospitals, laboratories, and biopharma institutions. Company updates commonly cover financial results, analysis volumes, customer additions, U.S. market expansion, and applications that analyze genomic and multimodal data for cancer and rare disorders.
Recurring developments include health-system collaborations, next-generation sequencing workflows for blood cancers and solid tumors, Liquid Biopsy and Enhanced Exomes applications, and management commentary on platform demand, gross margin, operating leverage, and biopharma activity.
SOPHiA GENETICS (Nasdaq: SOPH) reported second quarter 2026 revenue of $23.3 million, up 27% year-over-year. Reported gross margin was 64.6% and adjusted gross margin 72.1%, both slightly below the prior-year period. Net loss was $22.4 million, broadly unchanged, while adjusted EBITDA loss improved 27% to $8.8 million.
The company raised full-year 2026 revenue guidance to $94–$96 million (22–24% growth) and now expects adjusted EBITDA loss of $29–$32 million versus $41.5 million in 2025. Q2 volume reached 115,000 analyses, U.S. revenue grew 64%, liquid biopsy revenue grew 80%, and Net Dollar Retention increased to 117%. SOPHiA GENETICS signed a multi-year companion diagnostics agreement with AstraZeneca, an MOU with Memorial Sloan Kettering to form a joint venture, and completed an oversubscribed equity offering raising approximately $57.5 million, ending the quarter with $107.7 million in cash and cash equivalents.
SOPHiA GENETICS (Nasdaq: SOPH) announced a new multi-year global collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The agreement will advance two CDx programs using SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities.
According to SOPHiA GENETICS, its Solid Tumor application will be developed into a decentralized CDx, and its Hematological Oncology application will be developed and validated to support a CDx program for patients with blood cancer. The CDx solutions are intended to combine accurate biomarker detection with rapid, global deployment via the cloud-based SOPHiA DDM platform and the SOPHiA DDM MaxCare Program, allowing local laboratories worldwide to run the same validated, AI-powered analysis. SOPHiA GENETICS highlights that its technology-agnostic network connects more than 1,000 institutions across over 75 countries, aiming to expand access to innovative oncology treatments and support informed clinical decision-making in multiple healthcare systems.
SOPHiA GENETICS (Nasdaq: SOPH) will release its second quarter 2026 financial results before U.S. markets open on Tuesday, August 4, 2026. The company will hold a conference call and live webcast at 8:00 a.m. EDT / 2:00 p.m. CET to discuss results and business outlook, with a replay available on its Investor Relations website.
SOPHiA GENETICS (Nasdaq:SOPH) reported outcomes of its 2026 Annual General Meeting held on June 22, 2026. Shareholders elected co-founder Dr. Jurgi Camblong as Executive Chairman and Ross Muken to the Board; Muken becomes CEO effective July 1, 2026.
All AGM proposals passed, including director and committee elections, Board and Executive Committee compensation maxima, an amendment aligning Articles with the 2021 Equity Incentive Plan share replenishment, approval of 2025 financial statements and ESG Impact Summary, re-election of PwC as auditor, and new governance measures such as a rotating Lead Independent Director and regular executive sessions of independent directors.
SOPHiA GENETICS (Nasdaq: SOPH) closed an underwritten public offering of ordinary shares, raising $57.5 million in gross proceeds before fees and expenses. The company sold 12,104,900 shares at $4.75 each, including 1,578,900 additional shares from the underwriters’ fully exercised option, with all shares sold by the company.
SOPHiA GENETICS (Nasdaq:SOPH) priced a public offering of 10,526,000 ordinary shares at $4.75 per share, targeting gross proceeds of approximately $50 million before fees. All shares are issued by the company, with underwriters holding a 30-day option to buy up to 1,578,900 additional shares. The offering is expected to close on June 18, 2026, subject to customary conditions.
SOPHiA GENETICS (Nasdaq:SOPH) has commenced a proposed underwritten public offering of ordinary shares. The company plans to grant underwriters an option to buy up to an additional 15% of the shares at the offering price, less underwriting discount.
All shares will be newly issued by the company, with size, price and timing dependent on market and other conditions. TD Cowen is lead book-running manager. The offer will be made under an effective SEC Form F-3 shelf registration and will not be publicly offered or listed in Switzerland.
SOPHiA GENETICS (Nasdaq: SOPH) announced a leadership transition ahead of its June 18, 2026 AGM. Ross Muken, currently President, will become Chief Executive Officer and be proposed for the Board effective July 1, 2026. Co-founder Dr. Jurgi Camblong is nominated as Executive Chairman, while current Chairman Troy Cox is nominated for re-election as a non-executive director. The Board also plans a rotating Lead Independent Director role and regular executive sessions of independent directors, alongside an independent Board majority and fully independent committees.
SOPHiA GENETICS (NASDAQ:SOPH) signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center (MSK) on June 4, 2026 to form a joint venture. The envisioned precision medicine hub would combine MSK’s clinical data and leadership with SOPHiA’s Ai-driven SOPHiA DDM™ platform to advance multimodal precision oncology for patients and biopharma partners worldwide.
SOPHiA GENETICS (NASDAQ:SOPH) partnered with Synnovis to deliver MSK-ACCESS® liquid biopsy testing, powered by SOPHiA DDM™, to lung and breast cancer patients across the U.K. within NHS England’s blood test-first program.
The ctDNA-based test supports about 400 patients per month and is expected to reach 7,000 patients annually, potentially covering roughly one third of all ctDNA tests in England and enabling targeted therapies up to two weeks earlier.